Form 4: Cogent Biosciences Director Elects Equity Compensation, Receives Stock Options

Karen Jean Ferrante, a Director at Cogent Biosciences, Inc., received 3,314 stock options as part of her compensation, electing equity in lieu of cash for her services.

Summary

• Karen Jean Ferrante, a Director of Cogent Biosciences, Inc. (COGT), was granted 3,314 stock options.
• The transaction date for this grant was July 1, 2025.
• The options have an exercise price of $7.22 per share.
• These options become exercisable on July 1, 2025, and expire on July 1, 2035.
• The grant was made pursuant to the Issuer's non-employee director compensation plan, where the director elected to receive shares in lieu of cash compensation for services.
• The number of options granted was determined by dividing the cash compensation otherwise payable for the quarter by the Black-Scholes value of a single option calculated as of the grant date.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as a director choosing equity over cash indicates confidence in the company's future, aligning their interests with shareholders. It's a routine compensation event, so not highly impactful, but the choice of equity is a positive signal.

Positives

• The director's election to receive stock options instead of cash compensation aligns her interests more closely with those of shareholders, demonstrating confidence in the company's future performance.
• The grant is part of a structured non-employee director compensation plan, indicating a formalized approach to governance and executive incentives.

Negatives

• The issuance of new stock options, if exercised, could lead to a slight dilution of existing shareholder equity, although this is a standard practice for equity compensation.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the standard terms of the option grant.

Management Comments

• The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan.
• The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.

Industry Context

The practice of compensating non-employee directors with equity, such as stock options, is a common and widely accepted practice across various industries, including biotechnology and pharmaceuticals, to align director incentives with long-term shareholder value creation. This filing reflects a routine compensation event within the industry.

Comparison to Industry Standards

• Compensating non-employee directors with equity is a standard practice across publicly traded companies, including peers in the biotechnology sector like Moderna (MRNA) or BioNTech (BNTX), which often use restricted stock units (RSUs) or stock options to align director interests with company performance.
• The use of the Black-Scholes model to value options for compensation purposes is a widely accepted financial methodology, consistent with practices seen in companies like Pfizer (PFE) or Johnson & Johnson (JNJ) for valuing employee and director stock-based compensation.

Corporate Governance

Related Party Transactions

• The grant of stock options to Karen Jean Ferrante, a director, constitutes a related party transaction as it involves compensation provided by the issuer to a member of its board of directors.

Stakeholder Impact

• Shareholders: The issuance of options, if exercised, could lead to minor dilution, but the director's election of equity compensation aligns their interests with shareholder value creation.
• Management: This transaction reflects the company's adherence to its established compensation policies for non-employee directors.

Key Dates

Keywords

Cogent Biosciences, COGT, Form 4, SEC filing, insider transaction, stock options, director compensation, equity compensation, beneficial ownership, corporate governance